Results 1 to 2 of 2

Thread: AstraZeneca plc (LON:AZN)

  1. #1
    Super Moderator
    Join Date
    Apr 2015
    Posts
    2,383

    AstraZeneca plc (LON:AZN)

    AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities across the world. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

    Official website: www.astrazeneca.com

  2. #2
    RECOMMENDATION BUY
    TARGET 4240
    The Major trend of ASTRAZENECA PLC it is showing strength for buying .If it breaks the resistance level then one can initiate the buying position in the stock. If it breaks the level of 4197 then it can test resistance level for the target of 4240 with the stop loss of 4155.
    AstraZeneca plc (LON:AZN)-azn-png RSI is trading near to 57.47 level with positive bias, in upcoming session upside movement is expected.
    MACD and Signal line is sustaining above the zero level line.

    Skype jonsmith1091
    Attached Thumbnails Attached Thumbnails AstraZeneca plc (LON:AZN)-azn-png  

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
About us
StockMarketsReview.com provides news coverage, analysis and researches for world stock markets, commodities and currencies. We publish articles provided by experts of leading brokerage and investment companies. At our website investors can find daily, weekly and monthly reports, news, recommendations on the IPOs and fundamental analysis for stocks which are currently traded at the stock exchange.